Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 1524107, 9 pages
https://doi.org/10.1155/2017/1524107
Research Article

Serum Butyrylcholinesterase Activity: A Biomarker for Parkinson’s Disease and Related Dementia

1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
2Department of Neurology, Chongqing Fifth People’s Hospital, Chongqing, China

Correspondence should be addressed to You-Dong Wei; moc.361@6691iewgnoduoy

Received 29 March 2017; Revised 13 June 2017; Accepted 4 July 2017; Published 3 August 2017

Academic Editor: Cristiano Capurso

Copyright © 2017 Mei-Xue Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Jesse, S. Lehnert, O. Jahn et al., “Differential sialylation of serpin A1 in the early diagnosis of parkinson's disease dementia,” PLoS ONE, vol. 7, no. 11, Article ID e48783, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. L. V. Kalia and A. E. Lang, “Parkinson's disease,” The Lancet, vol. 386, no. 9996, pp. 896–912, 2015. View at Publisher · View at Google Scholar
  3. I. Litvan, J. G. Goldman, A. I. Tröster et al., “Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement disorder society task force guidelines,” Movement Disorders, vol. 27, no. 3, pp. 349–356, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Emre, P. J. Ford, B. Bilgiç, and E. Y. Uç, “Cognitive impairment and dementia in Parkinson's disease: practical issues and management,” Movement Disorders, vol. 29, no. 5, pp. 663–672, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Singh and J. T. O'Brien, “When should drug treatment be started for people with dementia?” Maturitas, vol. 62, no. 3, pp. 230–234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Klein, C. Eggers, E. Kalbe et al., “Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo,” Neurology, vol. 74, no. 11, pp. 885–892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. Q.-H. Zhang, A.-M. Li, S.-L. He et al., “Serum total cholinesterase activity on admission is associated with disease severity and outcome in patients with traumatic brain injury,” PLoS ONE, vol. 10, no. 6, Article ID e0129082, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. H.-Y. Chen, W. W.-J. Wang, C.-H. Chaou, and C.-C. Lin, “Prognostic value of serial serum cholinesterase activities in organophosphate poisoned patients,” American Journal of Emergency Medicine, vol. 27, no. 9, pp. 1034–1039, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Benmoyal-Segal, T. Vander, S. Shifman et al., “Acetylcholinesterase/paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease,” The FASEB Journal, vol. 19, no. 3, pp. 452–454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Berardelli, G. K. Wenning, A. Antonini et al., “EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease,” European Journal of Neurology, vol. 20, no. 1, pp. 16–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Dingova, T. Fazekas, P. Okuliarova, J. Strbova, M. Kucera, and A. Hrabovska, “Low plasma cholinesterase activities are associated with deficits in spatial orientation, reduced ability to perform basic activities of daily living, and low body mass index in patients with progressed alzheimer's disease,” Journal of Alzheimer's Disease, vol. 51, no. 3, pp. 801–813, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Hu, M.-X. Dong, H. Zhao, G.-H. Xu, and X.-Y. Qin, “Fibulin-5: a novel biomarker for evaluating severity and predicting prognosis in patients with acute intracerebral haemorrhage,” European Journal of Neurology, vol. 23, no. 7, pp. 1195–1201, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. M.-X. Dong, Q.-C. Hu, P. Shen et al., “Recombinant tissue plasminogen activator induces neurological side effects independent on thrombolysis in mechanical animal models of focal cerebral infarction: A systematic review and meta-analysis,” PLoS ONE, vol. 11, no. 7, Article ID e0158848, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Tinazzi, G. Abbruzzese, A. Antonini et al., “Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study,” Parkinsonism and Related Disorders, vol. 19, no. 12, pp. 1130–1135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Zhang, R. Katzman, D. Salmon et al., “The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age, gender, and education,” Annals of Neurology, vol. 27, no. 4, pp. 428–437, 1990. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Arbel, S. Shenhar-Tsarfaty, N. Waiskopf et al., “Decline in serum cholinesterase activities predicts 2-year major adverse cardiac events,” Molecular Medicine, vol. 20, pp. 38–45, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. O. O. Ogunkeye and A. I. Roluga, “Serum cholinesterase activity helps to distinguish between liver disease and non-liver disease aberration in liver function tests,” Pathophysiology, vol. 13, no. 2, pp. 91–93, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Santarpia, I. Grandone, F. Contaldo, and F. Pasanisi, “Butyrylcholinesterase as a prognostic marker: a review of the literature,” Journal of Cachexia, Sarcopenia and Muscle, vol. 4, no. 1, pp. 31–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. E. W. Randell, M. S. Mathews, H. Zhang, J. S. Seraj, and G. Sun, “Relationship between serum butyrylcholinesterase and the metabolic syndrome,” Clinical Biochemistry, vol. 38, no. 9, pp. 799–805, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Noyce, J. P. Bestwick, L. Silveira-Moriyama et al., “Meta-analysis of early nonmotor features and risk factors for Parkinson disease,” Annals of Neurology, vol. 72, no. 6, pp. 893–901, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. E. H. Sklan, A. Lowenthal, M. Korner et al., “Acetylcholinesterase/paraoxonase genotype and expression predict anxiety scores in health, risk factors, exercise training, and genetics study,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 15, pp. 5512–5517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. V. Dhananjayan, B. Ravichandran, N. Anitha, and H. Rajmohan, “Assessment of acetylcholinesterase and butyrylcholinesterase activities in blood plasma of agriculture workers,” Indian Journal of Occupational and Environmental Medicine, vol. 16, no. 3, pp. 127–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Kapka-Skrzypczak, K. Sawicki, M. Czajka, W. A. Turski, and M. Kruszewski, “Cholinesterase activity in blood and pesticide presence in sweat as biomarkers of children’s environmental exposure to crop protection chemicals,” Annals of Agricultural and Environmental Medicine, vol. 22, no. 3, pp. 478–482, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Kleiner-Fisman, M. B. Stern, and D. N. Fisman, “Health-related quality of life in Parkinson disease: correlation between health utilities index III and unified Parkinson's disease rating scale (UPDRS) in U.S. male veterans,” Health and Quality of Life Outcomes, vol. 8, article no. 91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Xiao, Z.-Z. Guan, C.-X. Wu, Y. Li, S.-X. Kuang, and J.-J. Pei, “Correlations between cholinesterase activity and cognitive scores in post-ischemic rats and patients with vascular dementia,” Cellular and Molecular Neurobiology, vol. 32, no. 3, pp. 399–407, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. E. B. Assayag, S. Shenhar-Tsarfaty, K. Ofek et al., “Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality,” Molecular Medicine, vol. 16, no. 7-8, pp. 278–286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Cerejeira, P. Batista, V. Nogueira, H. Firmino, A. Vaz-Serra, and E. B. Mukaetova-Ladinska, “Low preoperative plasma cholinesterase activity as a risk marker of postoperative delirium in elderly patients,” Age and Ageing, vol. 40, no. 5, Article ID afr053, pp. 621–626, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Ba, D.-Q. Wu, A.-Y. Qian, M. Zhang, and B. Xiong, “Dynamic changes of serum cholinesterase activity after severe trauma,” Journal of Zhejiang University: Science B, vol. 15, no. 12, pp. 1023–1031, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Bahloul, N. Baccouch, K. Chtara et al., “Value of serum cholinesterase activity in the diagnosis of septic shock due to bacterial infections,” Journal of Intensive Care Medicine, vol. 32, no. 5, pp. 346–352, 2016. View at Publisher · View at Google Scholar
  30. L.-P. Kamolz, H. Andel, M. Greher, D. Andel, G. Meiss, and M. Frey, “Serum cholinesterase activity in patients with burns,” Clinical Chemistry and Laboratory Medicine, vol. 40, no. 1, pp. 60–64, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Inácio Lunkes, F. Stefanello, D. Sausen Lunkes, V. Maria Morsch, M. R. C. Schetinger, and J. F. Gonçalves, “Serum cholinesterase activity in diabetes and associated pathologies,” Diabetes Research and Clinical Practice, vol. 72, no. 1, pp. 28–32, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Kálmán, A. Juhász, Z. Rakonczay et al., “Increased serum butyrylcholinesterase activity in type IIb hyperlipidaemic patients,” Life Sciences, vol. 75, no. 10, pp. 1195–1204, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Shenhar-Tsarfaty, S. Berliner, N. M. Bornstein, and H. Soreq, “Cholinesterases as biomarkers for parasympathetic dysfunction and inflammation-related disease,” Journal of Molecular Neuroscience, vol. 53, no. 3, pp. 298–305, 2014. View at Publisher · View at Google Scholar · View at Scopus